OSAS (Obstructive Sleep Apneas Syndrome) Completed Phase 3 Trials for Dexmedetomidine (DB00633)

Also known as: Obstructive Sleep Apnea (OSAS) / Sleep Apnea, Obstructive / Apnea, Obstructive Sleep / Obstructive Sleep Apnea / Obstructive Sleep Apnea (OSA) / Obstrutive Sleep Apnea / Sleep Obstructive Apnea / Sleep Apnea - Obstructive / Sleep Apnea, Obstructives / Sleep Apnea Obstructive (OSA) / OSA - Obstructive Sleep Apnea / Obstructive Sleep Apnea (SAOS) / Sleep Apnea Syndrome (OSAS) / OSA / OSAS / Obstructive Sleep Apnea Syndromes / Obstructive Sleep Apnea Syndrome and / Sleep Apnea Syndromes, Obstructive / Obstructive Sleep-Apnea Syndrome / Obstructive Sleep Apnoea Syndrome / Syndrome, Obstructive Sleep Apnea / Obstructive Sleep Apnea Syndrome (OSAS) / Obstructive Sleep Apnea Syndrome / Obstructive sleep apnea hypopnea / Sleep apnea syndrome / Sleep Apnea Syndromes / Sleep apnoea syndromes / Sleep apnea / Sleep apnoea syndrome / Apnea syndrome / Apnoea syndrome / Sleep apnoeas / Sleep apnoea

IndicationStatusPhase
DBCOND0039984 (OSAS (Obstructive Sleep Apneas Syndrome))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00468052Decrease Emergence Agitation and Provide Pain Relief for Children Undergoing Tonsillectomy & AdenoidectomyPrevention